Whole genome sequencing opens door for targeted Waldenström’s therapy

Whole genome sequencing opens door for targeted Waldenström’s therapy

VJHemOnc

1 year
821 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from hand-me-down to targeted approaches. The discovery of key growth and survival mutations, such as MYD88, has allowed the development of BTK inhibitors at the core of WM treatment. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
Up Next Autoplay
Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Category: Acute Myelogenous Leukemia
1,218 Views
VJHemOnc 1 year
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Category: Multiple Myeloma
935 Views
VJHemOnc 1 year
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Category: Multiple Myeloma
969 Views
VJHemOnc 1 year
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Category: General
767 Views
VJHemOnc 1 year
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
Category: General
275 Views
VJHemOnc 1 year
Judging the value of a clinical trial in hem-onc
Judging the value of a clinical trial in hem-onc
Category: General
54 Views
VJHemOnc 1 year
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Category: Multiple Myeloma
100 Views
VJHemOnc 1 year
Future treatment combinations for myeloma
Future treatment combinations for myeloma
Category: Melanoma and Skin Cancer
124 Views
VJHemOnc 1 year
Continuous vs. fixed duration therapy for multiple myeloma?
Continuous vs. fixed duration therapy for multiple myeloma?
Category: Multiple Myeloma
60 Views
VJHemOnc 1 year